Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Aviation Services Industry Update

    Business aviation activity reached its highest level in four years in the first half of 2026, supported by improved OEM deliveries and continued investment in aircraft servicing capacity.

    Read more

  • The Next Move for Consumer Packaged Goods: Strategic Plays for a Sector Under Pressure

    Valuation pressure, shifting demand, and stalled growth are forcing CPG leaders to rethink their playbook.

    Read more

  • Enliven Therapeutics, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Enliven Therapeutics, Inc. (ELVN $58.82), a late-stage biotech focused on developing ELVN-001, a potent and selective tyrosine kinase inhibitor (TKI), for the treatment of chronic myeloid leukemia (CML).

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures